Issue 22: Pharma Digest
The Digest is for you, the valued members of our pharma community. Receive the latest market movements, breaking pharma news, business-critical whitepapers and content, and updates on our exclusive executive summits. Don’t forget to subscribe using the button above.
Let's get started.
Take part in our 2024 industry predictions poll!??
As 2023 draws to a close, it’s imperative to reflect on where pharma has made significant progress and succeeded in delivering on patient commitments. Equally, as pharma teams set their strategy for the year to come, it’s vital to spotlight key challenges and other opportunities to excel.?
To capture an accurate picture of the industry as it stands and highlight key priorities for 2024, we want to invite our valued pharma community to participate in a short, anonymized poll addressing focus areas, emerging technologies, and internal shifts. The results will be presented in our 2024 Trend Report together with executive commentary.??
The Engagement Use Cases for AI
A wide array of AI tools are here now or coming that will help pharma sharpen its engagement approach across medical affairs and commercial. Read the article ‘The Engagement Use Cases for AI’ for more insights.
#AIinPharma #pharmatech
Global versus local: Mind the content gap
In the race to provide timely, tailored content for HCPs, pharma is rethinking its approach to how global and local content functions interact. Find out how to balance your HCP messaging in this article - Global versus local: Mind the content gap.
#pharmacontent #HCPengagement #HCPcontent
Top 5 pharma news to watch
1. Biden administration to impose inflation penalties on dozens of drugs (Reuters.com, December 14)
2. Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline (Fierce Pharma, December 14)
3. US FDA approves Merck's drug for kidney cancer (Reuters.com, December 15)
4. FDA Grants Priority Review To Amgen’s Tarlatamab Application For Advanced Small Cell Lung Cancer (Pharma Journalist, December 14)
5. Apellis eye drug likely to be rejected in Europe, company says (Biopharma Dive, December 14)
领英推荐
Event spotlight
Join us at Reuters Events: Pharma 2024 (16-18 April, Barcelona) where 1200+ commercial, marketing, medical, patient engagement, market access, RWE and digital health changemakers will come together under one roof to align purpose, unleash innovation and unlock healthcare.
Join us at Reuters Events: Pharma USA 2024 where North America’s visionary pharma changemakers, leading solution providers, patient experts, and industry heavyweights – from across Commercial, Marketing, Medical, Patient, Access, RWE and Cell & Gene Therapy - will catapult commercial excellence, guarantee equitable access to healthcare and accelerate cross-industry partnerships.
That rounds off Issue 22 of the Pharma Digest.
We'll be back in two weeks with more important news, market updates, pharma content, and updates on our events. Don’t forget to subscribe to receive a notification for our next bi-weekly digest.
As always, the Pharma team are on hand to answer your questions. You can connect with us on LinkedIn.
EU Team
USA Team
See you next time!